Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians

Detalhes bibliográficos
Autor(a) principal: Souza, Inara Espinelli Lemes de [UNIFESP]
Data de Publicação: 2006
Outros Autores: Zhang, W., Diaz, Ricardo Sobhie [UNIFESP], Chaloner, K., Klinzman, D., Stapleton, J. T.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://repositorio.unifesp.br/handle/11600/28608
http://dx.doi.org/10.1111/j.1468-1293.2005.00339.x
Resumo: ObjectivesGB virus C (GBV-C) infection is associated with delayed mortality in HIV-infected people in most, but not all, studies. Previous investigations of the effect of GBV-C viraemia on response to antiretroviral therapy (ART) were inconclusive. To determine the effect of GBV-C on ART, we retrospectively analysed plasma samples taken from patients in a prospective randomized clinical trial of ART in HIV-positive Brazilians.MethodsGBV-C viraemia was characterized by testing stored serum samples from 175 participants by reverse transcriptase-polymerase chain reaction (RT-PCR). Subjects were randomized to receive indinavir (n=59), zidovudine and lamivudine (n=58), or zidovudine, lamivudine and indinavir (n=58). the effect of GBV-C viraemia on the average change in HIV viral load and CD4 count following initiation of therapy was evaluated in a multiple regression analysis.ResultsThe prevalence of GBV-C viraemia was similar to that observed in previous studies (24%). HIV viral load decreased following ART to a significantly greater extent in patients with GBV-C viraemia (by 0.48 log(10) HIV-1 RNA copies/mL, P=0.009, adjusting for age, ART group, and baseline CD4 count). Although there was no significant difference in change in CD4 count between individuals with and without GBV-C viraemia overall, CD4 counts were higher following 48 weeks of therapy in GBV-C viraemic individuals receiving the least potent ART regimen (zidovudine and lamivudine) compared with those without GBV-C infection.ConclusionsGBV-C viraemia is associated with an enhanced reduction of HIV viral load in response to ART. in this study of treatment-naive individuals during 48 weeks of follow up, patients with GBV-C viraemia had reductions in HIV viral load that were approximately 0.5 log copies/mL greater than those found in patients without GBV-C viraemia. This is similar to reductions observed with nucleoside reverse transcriptase inhibitors.
id UFSP_1c68496e9d815ca1dcc9e1385e604b71
oai_identifier_str oai:repositorio.unifesp.br:11600/28608
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Souza, Inara Espinelli Lemes de [UNIFESP]Zhang, W.Diaz, Ricardo Sobhie [UNIFESP]Chaloner, K.Klinzman, D.Stapleton, J. T.Univ IowaIowa City Vet AdmUniversidade Federal de São Paulo (UNIFESP)2016-01-24T12:38:14Z2016-01-24T12:38:14Z2006-01-01Hiv Medicine. Oxford: Blackwell Publishing, v. 7, n. 1, p. 25-31, 2006.1464-2662http://repositorio.unifesp.br/handle/11600/28608http://dx.doi.org/10.1111/j.1468-1293.2005.00339.x10.1111/j.1468-1293.2005.00339.xWOS:000233623500004ObjectivesGB virus C (GBV-C) infection is associated with delayed mortality in HIV-infected people in most, but not all, studies. Previous investigations of the effect of GBV-C viraemia on response to antiretroviral therapy (ART) were inconclusive. To determine the effect of GBV-C on ART, we retrospectively analysed plasma samples taken from patients in a prospective randomized clinical trial of ART in HIV-positive Brazilians.MethodsGBV-C viraemia was characterized by testing stored serum samples from 175 participants by reverse transcriptase-polymerase chain reaction (RT-PCR). Subjects were randomized to receive indinavir (n=59), zidovudine and lamivudine (n=58), or zidovudine, lamivudine and indinavir (n=58). the effect of GBV-C viraemia on the average change in HIV viral load and CD4 count following initiation of therapy was evaluated in a multiple regression analysis.ResultsThe prevalence of GBV-C viraemia was similar to that observed in previous studies (24%). HIV viral load decreased following ART to a significantly greater extent in patients with GBV-C viraemia (by 0.48 log(10) HIV-1 RNA copies/mL, P=0.009, adjusting for age, ART group, and baseline CD4 count). Although there was no significant difference in change in CD4 count between individuals with and without GBV-C viraemia overall, CD4 counts were higher following 48 weeks of therapy in GBV-C viraemic individuals receiving the least potent ART regimen (zidovudine and lamivudine) compared with those without GBV-C infection.ConclusionsGBV-C viraemia is associated with an enhanced reduction of HIV viral load in response to ART. in this study of treatment-naive individuals during 48 weeks of follow up, patients with GBV-C viraemia had reductions in HIV viral load that were approximately 0.5 log copies/mL greater than those found in patients without GBV-C viraemia. This is similar to reductions observed with nucleoside reverse transcriptase inhibitors.Univ Iowa, Dept Internal Med, Roy & Lucille Carver Coll Med, Iowa City, IA 52242 USAIowa City Vet Adm, Med Ctr, Iowa City, IA USAUniversidade Federal de São Paulo, Paulista Sch Med, Div Infect Dis, São Paulo, BrazilUniv Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USAUniversidade Federal de São Paulo, Paulista Sch Med, Div Infect Dis, São Paulo, BrazilWeb of Science25-31engBlackwell PublishingHiv Medicineantiretroviral therapyGB virus type CGBV-Chepatitis GEffect of GB virus C on response to antiretroviral therapy in HIV-infected Braziliansinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/286082022-06-02 09:34:57.599metadata only accessoai:repositorio.unifesp.br:11600/28608Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:16:13.622639Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.en.fl_str_mv Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians
title Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians
spellingShingle Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians
Souza, Inara Espinelli Lemes de [UNIFESP]
antiretroviral therapy
GB virus type C
GBV-C
hepatitis G
title_short Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians
title_full Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians
title_fullStr Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians
title_full_unstemmed Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians
title_sort Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians
author Souza, Inara Espinelli Lemes de [UNIFESP]
author_facet Souza, Inara Espinelli Lemes de [UNIFESP]
Zhang, W.
Diaz, Ricardo Sobhie [UNIFESP]
Chaloner, K.
Klinzman, D.
Stapleton, J. T.
author_role author
author2 Zhang, W.
Diaz, Ricardo Sobhie [UNIFESP]
Chaloner, K.
Klinzman, D.
Stapleton, J. T.
author2_role author
author
author
author
author
dc.contributor.institution.none.fl_str_mv Univ Iowa
Iowa City Vet Adm
Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Souza, Inara Espinelli Lemes de [UNIFESP]
Zhang, W.
Diaz, Ricardo Sobhie [UNIFESP]
Chaloner, K.
Klinzman, D.
Stapleton, J. T.
dc.subject.eng.fl_str_mv antiretroviral therapy
GB virus type C
GBV-C
hepatitis G
topic antiretroviral therapy
GB virus type C
GBV-C
hepatitis G
description ObjectivesGB virus C (GBV-C) infection is associated with delayed mortality in HIV-infected people in most, but not all, studies. Previous investigations of the effect of GBV-C viraemia on response to antiretroviral therapy (ART) were inconclusive. To determine the effect of GBV-C on ART, we retrospectively analysed plasma samples taken from patients in a prospective randomized clinical trial of ART in HIV-positive Brazilians.MethodsGBV-C viraemia was characterized by testing stored serum samples from 175 participants by reverse transcriptase-polymerase chain reaction (RT-PCR). Subjects were randomized to receive indinavir (n=59), zidovudine and lamivudine (n=58), or zidovudine, lamivudine and indinavir (n=58). the effect of GBV-C viraemia on the average change in HIV viral load and CD4 count following initiation of therapy was evaluated in a multiple regression analysis.ResultsThe prevalence of GBV-C viraemia was similar to that observed in previous studies (24%). HIV viral load decreased following ART to a significantly greater extent in patients with GBV-C viraemia (by 0.48 log(10) HIV-1 RNA copies/mL, P=0.009, adjusting for age, ART group, and baseline CD4 count). Although there was no significant difference in change in CD4 count between individuals with and without GBV-C viraemia overall, CD4 counts were higher following 48 weeks of therapy in GBV-C viraemic individuals receiving the least potent ART regimen (zidovudine and lamivudine) compared with those without GBV-C infection.ConclusionsGBV-C viraemia is associated with an enhanced reduction of HIV viral load in response to ART. in this study of treatment-naive individuals during 48 weeks of follow up, patients with GBV-C viraemia had reductions in HIV viral load that were approximately 0.5 log copies/mL greater than those found in patients without GBV-C viraemia. This is similar to reductions observed with nucleoside reverse transcriptase inhibitors.
publishDate 2006
dc.date.issued.fl_str_mv 2006-01-01
dc.date.accessioned.fl_str_mv 2016-01-24T12:38:14Z
dc.date.available.fl_str_mv 2016-01-24T12:38:14Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv Hiv Medicine. Oxford: Blackwell Publishing, v. 7, n. 1, p. 25-31, 2006.
dc.identifier.uri.fl_str_mv http://repositorio.unifesp.br/handle/11600/28608
http://dx.doi.org/10.1111/j.1468-1293.2005.00339.x
dc.identifier.issn.none.fl_str_mv 1464-2662
dc.identifier.doi.none.fl_str_mv 10.1111/j.1468-1293.2005.00339.x
dc.identifier.wos.none.fl_str_mv WOS:000233623500004
identifier_str_mv Hiv Medicine. Oxford: Blackwell Publishing, v. 7, n. 1, p. 25-31, 2006.
1464-2662
10.1111/j.1468-1293.2005.00339.x
WOS:000233623500004
url http://repositorio.unifesp.br/handle/11600/28608
http://dx.doi.org/10.1111/j.1468-1293.2005.00339.x
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.none.fl_str_mv Hiv Medicine
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 25-31
dc.publisher.none.fl_str_mv Blackwell Publishing
publisher.none.fl_str_mv Blackwell Publishing
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv
_version_ 1783460270154186752